The Europe mycoplasma testing market was worth USD 141.75 Million in 2018 and is estimated to be growing at a CAGR of 12.6%, to reach USD 256.57 Million by 2023. Mycoplasma is a prokaryotic organism which is often responsible for the contamination of cell cultures. This organism has the ability to alter certain features of cell physiology resulting in the invalidity of the experiments conducted.
Because of its small size, they easily pass through filters that usually prevent contamination from fungus and bacteria and easily spread to other cell cultures in the laboratory. Hence, it is necessary that cell cultures entering a laboratory are to be tested to detect the presence of mycoplasma and the laboratory itself is also to be tested. There are many mycoplasma testing methods available in the market.
Rising expenditure for research and development activities in pharmaceutical and biotechnology companies, increased R&D activities in life sciences and increasing incidence of mycoplasma infections in cell cultures are the major factors driving the growth of mycoplasma testing market in Europe region. High degree of market consolidation and increase in expenditure for mycoplasma testing are the major restraining factors for the market.
The Europe mycoplasma testing market is segmented on the basis of product, technique, application, end user and region. On the basis of product, the market is segmented into kits & reagents, instruments and services. Kits & reagent is expected to hold the largest market share in this segment. This is due to the requirement for repeated purchase of these products as they are consumed with each test while instruments need not be purchased frequently. Based on technique, the market is segmented into PCR, ELSA, Direct Assays, Indirect Assays, Microbial culture techniques, Enzymatic Methods, and DNA Staining. PCR technique is projected to lead the market in this segment as it is highly accepted in life sciences research due to the speed and flexibility of this technique. Based on application, the mycoplasma testing market is segmented into Cell Line Testing, Virus Testing, End-Of-Production Cell Testing and other applications. Cell line testing is expected to lead the market and is also one of the rapidly growing segments due to the increasing application of cell line testing in research as well as biopharmaceutical production. Based on end user, the market is segmented into Pharmaceutical Companies, Contract research organizations, Academic Research Institutes and Cell Banks. Pharmaceutical companies segment holds the largest market share due to the increasing R&D activities in pharmaceutical and biotechnology companies.
Based on geography, the Europe market for mycoplasma testing is segmented into UK, Germany, France, Spain and Italy regions. Germany leads the mycoplasma testing market owing to the increase in number of pharmaceutical industries in this region.
The major companies in the mycoplasma testing market are Thermo Fisher Scientific Inc., American Type Culture Collection, Minerva Biolabs GmbH, Charles River Laboratories International, Inc., Gibraltar Laboratories, Biological Industries Israel Beit Haemek Ltd., Sartorius AG, Lonza Group Ltd., Merck KGaA, Roche Diagnostics, SGS S.A., InvivoGen, PromoCell GmbH, and WuXi AppTec.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Kits & Reagent
5.1.3 Instruments
5.1.4 Services
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Technique
5.2.1 Introduction
5.2.2 PCR
5.2.3 ELSA
5.2.4 Direct Assays
5.2.5 Indirect Assays
5.2.6 Microbial culture techniques
5.2.7 Enzymatic Methods
5.2.8 DNA Staining
5.2.9 Y-o-Y Growth Analysis, By Technique
5.2.10 Market Attractiveness Analysis, By Technique
5.2.11 Market Share Analysis, By Technique
5.3 Application
5.3.1 Introduction
5.3.2 Cell Line Testing
5.3.3 Virus Testing
5.3.4 End-Of-Production Cell Testing
5.3.5 Other Applications
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.1 Introduction
5.4.2 Pharmaceutical Companies
5.4.3 Contract Research Organizations
5.4.4 Academic Research Institutes
5.4.5 Cell Banks
5.4.6 Y-o-Y Growth Analysis, By End User
5.4.7 Market Attractiveness Analysis, By End User
5.4.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Technique
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Technique
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Technique
6.1.5.4 By Application
6.1.5.5 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Minerva Biolabs GmbH
8.3 Charles River Laboratories International
8.4 Gibraltar Laboratories
8.5 Sartorius AG
8.6 Lonza Group Ltd.
8.7 Merck KGaA
8.8 Roche Diagnostics
8.9 SGS S.A.
8.10 American Type Culture Collection
8.11 InvivoGen
8.12 PromoCell GmbH
8.13 Biological Industries Israel Beit Haemek Ltd.
8.14 WuXi AppTec
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
